What is Immatics?
Immatics operates at the intersection of biotechnology and precision medicine, focusing on the discovery of novel targets for cancer immunotherapies. By developing highly specific T cell receptors, the company aims to trigger robust immune responses against malignant cells. Its business model is anchored in both internal R&D and strategic partnerships with global pharmaceutical leaders, positioning the firm as a critical player in the next generation of oncology therapeutics. The company's deep technical expertise in TCR-based modalities provides a competitive moat in the rapidly evolving landscape of personalized cancer care.
How much funding has Immatics raised?
Immatics has raised a total of $392.5M across 8 funding rounds:
Series A
$9.9M
Series B
$52.1M
Series C
$71.2M
Series D
$16.3M
Other Financing Round
$30M
Other Financing Round
$58M
Share Placement
$35M
Private Equity
$120M
Series A (2004): $9.9M with participation from EMBL Ventures, Merifin Capital, 3i Group, and VINCI CAPITAL
Series B (2007): $52.1M led by DH Capital, NTEC, KfW, OH Beteiligungen, and 3i Group
Series C (2010): $71.2M supported by MIG Capital, AT Impf, and dievini Hopp Biotech Holding
Series D (2013): $16.3M featuring dievini Hopp BioTech, Wellington Partners, and MIG Funds
Other Financing Round (2017): $30M backed by Amgen
Other Financing Round (2017): $58M with participation from AT Impf, dievini Hopp Biotech Holding, and Amgen
Share Placement (2023): $35M led by Bristol-Myers Squibb
Private Equity (2023): $120M supported by Moderna
Key Investors in Immatics
Moderna
Moderna is a pioneer in mRNA medicine, reshaping the development of vaccines and therapeutics across infectious diseases and oncology.
Amgen
Amgen is a leading multinational biotechnology firm that has been at the forefront of scientific innovation in medicine since 1980.
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical organization focused on discovering and developing innovative treatments for serious diseases, including cancer.
What's next for Immatics?
With the recent capital injection, Immatics is well-positioned to accelerate its clinical-stage programs and enhance its manufacturing capabilities for cell-based therapies. The strategic focus will likely remain on advancing its lead candidates through regulatory milestones while leveraging its existing pharmaceutical alliances to broaden the reach of its therapeutic platform. As the company transitions into a more mature phase of commercial readiness, the emphasis will shift toward optimizing patient access and demonstrating long-term clinical efficacy in diverse oncology indications.
See full Immatics company page
